ST. LOUIS, Dec. 22, 2023 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today it will present at the 42nd Annual J. P. Morgan Healthcare Conference, to be held Monday, January 8 – Thursday, January 11, 2024, in San Francisco.
Centene will present on Tuesday, January 9, at 9:00 a.m. Pacific Time (PT). A simultaneous live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare24/sessions/49363-centene-corporation/webcast?gpu_only=true&kiosk=true.
A webcast replay will be available following the presentation on Centene's website, www.centene.com, under the Investors section.
About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems, and capabilities so that it can better serve its members, providers, local communities and government partners.
Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com/.
Last Trade: | US$58.83 |
Daily Change: | 1.37 2.38 |
Daily Volume: | 5,073,575 |
Market Cap: | US$29.700B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB